VERU INC. Finance Lease, Right-of-Use Asset, Amortization
VERU INC. (VERU) reported Finance Lease, Right-of-Use Asset, Amortization of $3.63 thousand for the 12-month period ending 2022-09-30, per its 10-K/A filed 2024-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2024-04-01
- VERU INC. finance lease, right-of-use asset, amortization for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. finance lease, right-of-use asset, amortization for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. finance lease, right-of-use asset, amortization for the quarter ending 2022-03-31 was $1.45K, a 33.32% decline year-over-year.
- VERU INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $2.18K, a 0.00% change year-over-year.
- VERU INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $3.63K, a 58.41% decline from fiscal 2021.
- VERU INC. finance lease, right-of-use asset, amortization for fiscal 2021 was $8.73K, a 0.21% increase from fiscal 2020.
- VERU INC. finance lease, right-of-use asset, amortization for fiscal 2020 was $8.71K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $1.45K derived: sum of 3 quarters · filed 2024-04-01 | $3.63K 10-K/A · filed 2024-04-01 |
| 2022-06-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $1.45K derived: sum of 2 quarters · filed 2023-11-15 | $3.63K 10-Q/A · filed 2023-11-15 | $5.83K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-03-31 | $1.45K 10-Q · filed 2023-05-11 | $3.63K 10-Q · filed 2023-05-11 | $5.83K derived: sum of 3 quarters · filed 2023-05-11 | $8.01K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.18K 10-Q · filed 2023-02-09 | $4.37K derived: sum of 2 quarters · filed 2023-02-09 | $6.55K derived: sum of 3 quarters · filed 2023-02-09 | $8.73K derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $2.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $4.37K derived: sum of 2 quarters · filed 2022-12-05 | $6.55K derived: sum of 3 quarters · filed 2022-12-05 | $8.73K 10-K · filed 2022-12-05 |
| 2021-06-30 | $2.18K 10-Q · filed 2022-08-11 | $4.36K derived: sum of 2 quarters · filed 2022-08-11 | $6.54K 10-Q · filed 2022-08-11 | $8.71K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.18K 10-Q · filed 2022-05-12 | $4.36K 10-Q · filed 2022-05-12 | $6.54K derived: sum of 3 quarters · filed 2022-05-12 | $8.71K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.18K 10-Q · filed 2022-02-09 | $4.36K derived: sum of 2 quarters · filed 2022-02-09 | $6.53K derived: sum of 3 quarters · filed 2022-02-09 | $8.71K derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $2.18K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $4.36K derived: sum of 2 quarters · filed 2021-12-02 | $6.54K derived: sum of 3 quarters · filed 2021-12-02 | $8.71K 10-K · filed 2021-12-02 |
| 2020-06-30 | $2.18K 10-Q · filed 2021-08-12 | $4.36K derived: sum of 2 quarters · filed 2021-08-12 | $6.54K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $2.18K 10-Q · filed 2021-05-12 | $4.36K 10-Q · filed 2021-05-12 | ||
| 2019-12-31 | $2.18K 10-Q · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |